Navigation Links
Nuvelo Announces Publication of Preclinical Study Results,Demonstrating the Potential of NTB-A as a New Target for Leukemia,and Lymphomas

als.

    (1) Byrd, J.C., Stilgenbauer, S. & Flinn, I.W. (2004) Chronic lymphocytic

        leukemia. Hematology (American Society of Hematology Education

        Program), 1, 163-183.

    (2) Kokhaei, P., Palma, M., Mellstedt, H. & Choudhury, A. (2005) Biology

        and treatment of chronic lymphocytic leukemia. Annals of Oncology,

        16(Suppl. 2), ii113-123.

    (3) Kuriakose, P. (2005) Targeted therapy for hematologic malignancies.

        Cancer Control, 12, 82-90.

    (4) Ortin, M. (2005) Immunotherapy of hematological malignancies: what is

        new? Annals of Oncology, 16(Suppl. 2), ii53-62.

About Nuvelo's Cancer Antibody Program

Nuvelo's cancer antibody pipeline includes advanced targets in leukemia and lymphoma, and earlier-stage solid tumor targets in colon, lung and breast cancers. Nuvelo has developed monoclonal antibodies specific to these targets and is testing them in animal models. These models test the ability of antibodies to shrink human tumor tissue growing in immunodeficient mice (xenografts). Nuvelo is continuing to evaluate leading monoclonal antibodies in more advanced preclinical studies, and those that are sufficiently validated in animal models may move into to clinical trials.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. Nuvelo is also advancing an emerging oncology
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:11/20/2009)...e-FirstCall/ -- Smith & Nephew ( SNN, LSE: SN)...signing of a technology development contract with ...ead to the creation of a fracture fixation system ...bs of soldiers who sustain battlefield injuries. ,...ects Agency (DARPA), the central research and deve...
(Date:11/19/2009)...-- In response to an ever-increasing number of web...peration Pangea II, involving 24 countries, was co...ation,s International Medical Products Anti-Counte...rs of buying medicines online. ,, The week long... and the seizure of thousands of potentially harmf...
(Date:11/19/2009)...- Riverain Medical announced today that the compan... imaging distributor Christie Group to offer SoftV...CAD. The exclusive agreement will bring Dayton, Oh...an market through Christie Group,s established and...Chest Imaging increases the clarity of digital che...
Breaking Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2Riverain Medical Partners With The Christie Group In Canada To Offer SoftView Enhanced Chest Imaging and OnGuard Chest X-Ray CAD Technologies 2New Complimentary Wallet Card to Tackle Concussions Head On 58903 1New Complimentary Wallet Card to Tackle Concussions Head On 58903 2Hugh Chatham Adopts Star Trek Technology with the Use of Palm Identify to Prevent Medical ID Theft 58898 1Hugh Chatham Adopts Star Trek Technology with the Use of Palm Identify to Prevent Medical ID Theft 58898 2U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 1U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 2U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 3
...Enrollment in First Pivotal Phase 3 Avanafil Study...Calif., May 13 VIVUS, Inc. (Nasdaq: VVUS ), a b...xt-generation therapies to address unmet needs in ...ed that it has initiated an open label safety stud..., in males with erectile dysfunction (ED). , , ...
...WASHINGTON, May 12 The Epilepsy Foundation recent...sy, whose seizures have been controlled with a con...reased seizures, greater side effects or sudden de...ersion of an antiepileptic drug (AED) to another, ...o-brand or generic-to-generic. , , See video fro...
Other Medicine Technology:VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction 2VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction 3VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful 2
(Date:11/20/2009)... , , WASHINGTON, Nov. 20 /PRNewswire-USN...is urging senators to modify health care reform le...anguage regarding a health insurance individual co...ve and enforceable mandate will minimize adverse s...rating rules prescribed by the bill. ,, "The in...
(Date:11/20/2009)... , Senators and Congressm...Trouble Over their Health Care Vote , ...009 -- Senators and congressmen running for re-ele...by political guru Charlie Cook, may come to regret...lth care bill, according to a breaking Zogby Inter...
(Date:11/20/2009)... , , ST. LOUIS, Nov. 20 /PRNewswire-Fir...day announced that it will present at the Bank of ...e held December 2-3, 2009, at the Crowne Plaza Hot...ll present Wednesday, December 2nd at 8:30 a.m. Ea... may access a live, audio webcast of Centene,s pre...
(Date:11/20/2009)... , , LAS VEGAS, Nov. 20 /PRNewswire-USNewsw...rry, Executive Director of the Nevada Health Care ...tion (NHCA) commends and thanks Senate Majority Le...ation a step closer toward our goal of protecting ...rsing home care, and preserving the strength and v...
(Date:11/20/2009)... , Long durations of exposure to formaldehyde use...iated with an increased risk of death from myeloid...ne November 20 in the Journal of the National Can...cess mortality from lymphohematopoietic malignanci...nd funeral industry workers, all of whom may have ...
Breaking Medicine News(10 mins):Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2
...ures Build Upon the Trusted Experience 100 Million...epend Upon, SAN FRANCISCO, July 14 BabyCenter, L...pectant parents around the world, announced,today ...d expert voice parents have depended on from BabyC...
...them return to prior playing level 83% of time, re...News) -- One of the country,s leading sports docto...sprained elbows in young athletes, a fact that ref...ting their arms at risk, said co-author Dr. E. Lyl...
..., July 14 Abaxis, Inc.,(Nasdaq: ABAX ), a medica...od analysis systems, has scheduled a conference ca...quarter of fiscal year 2009, ended June 30,2008. T... can listen via a live Internet web cast, which ca...
... Vical Incorporated,(Nasdaq: VICL ) today announ...n safety and immunogenicity data from a Phase 1 tr...pandemic influenza DNA vaccines on Thursday,July 1...y R. Smith, Ph.D., will,present preliminary safety...
... MS -- For the millions of junior,high, high schoo...tly, the,idea of returning to the classroom may be...wscom.com/cgi-bin/prnh/20080714/NYFNSP04 ), Whil...ing as hard to "fit in" as they do to improve thei...
...Monthly Fitness Program Promises to Take Beachbody...BEVERLY HILLS, Calif., July 14 In honor of his 50...er Tony Horton has released,the next in a long lin...ul fitness programs including Power,90(R), P90X(R)...
Other Medicine News:Health News:BabyCenter Launches Social Network for Largest Parenting Community Online 2Health News:BabyCenter Launches Social Network for Largest Parenting Community Online 3Health News:Elbow Injuries on Rise Among Young Athletes 2Health News:Elbow Injuries on Rise Among Young Athletes 3Health News:Abaxis to Report First Quarter Fiscal 2009 Financial Results Thursday, July 24, 2008 2Health News:Vical to Present Phase 1 Data for Vaxfectin(R)-Formulated Pandemic Influenza DNA Vaccines 2Health News:Vical to Present Phase 1 Data for Vaxfectin(R)-Formulated Pandemic Influenza DNA Vaccines 3Health News:Body Image is a Concern for Students of All Ages 2Health News:Beachbody(R) Launches One on One with Tony Horton 2
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
Medicine Products: